News
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...
Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...
National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...
The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in. | Novo ...
Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results